Metpamid Nedir – Ne İşe Yarar – Yan Etkileri

Metpamid, metoklopramid etken maddesini içeren, bulantı ve kusmayı önleyen ve tedavi eden bir ilaçtır.

Metpamid, beynin mide bulantısını ve kusmayı engelleyen bölgesindeki reseptörleri uyararak etki gösterir. Ayrıca, mide ve bağırsakların hareketlerini artırarak yiyeceklerin daha hızlı hazmedilmesine yardımcı olur.

Metpamid ne için kullanılır?

Metpamid, aşağıdaki durumlarda kullanılabilir:

• Bulantı ve kusmanın tedavisinde: Mide bulantısı ve kusma, çeşitli nedenlerle ortaya çıkabilir. Metpamid, mide bulantısı ve kusmanın tedavisinde etkili bir ilaçtır.
• Kemoterapi veya radyoterapi sonrası bulantı ve kusmanın önlenmesinde: Kemoterapi ve radyoterapi, kanser tedavisinde kullanılan yaygın yöntemlerdir. Bu tedaviler, bulantı ve kusmaya neden olabilir. Metpamid, kemoterapi veya radyoterapi sonrası bulantı ve kusmanın önlenmesinde etkili bir ilaçtır.
• Akut migrene bağlı bulantı ve kusmanın tedavisinde: Migren, baş ağrısı ile birlikte bulantı ve kusmaya neden olabilen bir hastalıktır. Metpamid, akut migrene bağlı bulantı ve kusmanın tedavisinde etkili bir ilaçtır.

Metpamid yan etkileri nedir?

Metpamid’in yaygın görülen yan etkileri şunlardır:

• Baş dönmesi
• Uyku hali
• Halsizlik
• Kabızlık
• İshal
• Ağız kuruluğu
• Karın ağrısı

Bu yan etkiler genellikle hafiftir ve tedavinin kesilmesiyle geçer. Ancak, yan etkilerin şiddetli veya devam etmesi durumunda doktorunuza veya eczacınıza danışınız.

Metpamid’in diğer yan etkileri şunlardır:

• Alerjik reaksiyonlar
• Extrapiramidal bozukluklar
• Düşük tansiyon
• Aritmi
• Sarılık
• İdrarda kan

Metpamid muadili nedir?

Metpamid’in muadilleri şunlardır:

• Tablet:
  • Anti-Nausea
  • Emoject
  • Metoplon
  • Nastifran
  • Pramed
  • Primperan
  • Primsel
  • Turktipsan
  • Metoklopramid Hidroklorur
  • Vomepram
• Enjeksiyon:
  • Metoclopramid HCl Enj.
  • Primperan Enj.

Metpamid’in muadilleri, tablet, oral çözelti veya enjeksiyon şeklinde kullanılabilir. Etken madde miktarı ve dozajları da farklı olabilir.

Metpamid’in muadili seçerken, doktorunuza veya eczacınıza danışmanız önemlidir.

Metpamid nasıl kullanılır?

Tablet:

Metpamid tablet, ağızdan alınır. Bir defalık doz, yetişkinlerde 10 mg, 6-14 yaş arası çocuklarda 2.5-5 mg ve 6 yaşından küçük çocuklarda 0.1 mg/kg’dır. Bu dozlar günde 3-4 defa tekrarlanabilir.

Oral çözelti:

Metpamid oral çözelti, ağızdan alınır. Bir defalık doz, yetişkinlerde 10 mg (2 ölçek), 6-14 yaş arası çocuklarda 2.5-5 mg (1/2-1 ölçek) ve 6 yaşından küçük çocuklarda 0.1 mg/kg’dır. Bu dozlar günde 3-4 defa tekrarlanabilir.

Enjeksiyon:

Metpamid enjeksiyon, kas içi veya damar içi olarak uygulanır. Bir defalık doz, yetişkinlerde 10 mg’dır, günde en fazla 3 kere tekrarlanabilir.

Metpamid aç mı tok mu kullanılır?

Metpamid, aç karnına, öğünlerden yaklaşık 30 dakika önce alınmalıdır. Bu şekilde, ilaç daha iyi emilebilir ve daha etkili olur.

Özet

Sonuç olarak, Metpamid, bulantı ve kusmayı önlemek ve tedavi etmek için etkili bir ilaçtır. Ancak, ilacın yan etkileri olabileceğinden, doktorunuza veya eczacınıza danışmadan kullanmamalısınız.

Kaynakça

Atıf ve kaynakça yazımı hakkında daha fazla bilgi edinmek için bu bağlantıları takip edin.
https://www.mayoclinic.org/drugs-supplements/metoclopramide-oral-route/description/drg-20064784?sscid=b1k7_nas44&
https://www.nhs.uk/medicines/metoclopramide/
https://www.ncbi.nlm.nih.gov/books/NBK519517/
https://medlineplus.gov/druginfo/meds/a684035.html
https://www.webmd.com/drugs/2/drug-8679-2217/metoclopramide-oral/metoclopramide-disintegrating-tablet-oral/details
https://www.drugs.com/metoclopramide.html

Referanslar

Rettura F, Bronzini F, Campigotto M, Lambiase C, Pancetti A, Berti G, Marchi S, de Bortoli N, Zerbib F, Savarino E, Bellini M. Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med (Lausanne). 2021;8:765061. 

Shakhatreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):711-721. 

Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017 Sep;23(14 Suppl):S259-S265. 

Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C, Gibson P, Maan C, Stefin N, Sung L, Dupuis LL. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. Pediatr Blood Cancer. 2016 Jul;63(7):1144-51.

De Oliveira GS, Castro-Alves LJ, Chang R, Yaghmour E, McCarthy RJ. Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii’s studies. Br J Anaesth. 2012 Nov;109(5):688-97.

Najjar M, Hall T, Estupinan B. Metoclopramide for Acute Migraine Treatment in the Emergency Department: An Effective Alternative to Opioids. Cureus. 2017 Apr 20;9(4):e1181.

Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lantéri-Minet M, Braschinsky M, Del Rio MS, Daniel O, Özge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-514.

Tan PC, Khine PP, Vallikkannu N, Omar SZ. Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol. 2010 May;115(5):975-981.

Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol. 2014 Jun;123(6):1272-1279.

Akiyama M, Yanagisawa T, Yuza Y, Yokoi K, Ariga M, Fujisawa K, Hoshi Y, Eto Y. Successful treatment of Diamond-Blackfan anemia with metoclopramide. Am J Hematol. 2005 Apr;78(4):295-8.

Bartels M, Bierings M. How I manage children with Diamond-Blackfan anaemia. Br J Haematol. 2019 Jan;184(2):123-133.

Vijayaraghavan R, Maiwall R, Arora V, Choudhary A, Benjamin J, Aggarwal P, Jamwal KD, Kumar G, Joshi YK, Sarin SK. Reversal of Feed Intolerance by Prokinetics Improves Survival in Critically Ill Cirrhosis Patients. Dig Dis Sci. 2022 Aug;67(8):4223-4233.

Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010;5(5):653-662.

Ge S, Mendley SR, Gerhart JG, Melloni C, Hornik CP, Sullivan JE, Atz A, Delmore P, Tremoulet A, Harper B, Payne E, Lin S, Erinjeri J, Cohen-Wolkowiez M, Gonzalez D., Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Population Pharmacokinetics of Metoclopramide in Infants, Children, and Adolescents. Clin Transl Sci. 2020 Nov;13(6):1189-1198. 

Sanger GJ, Andrews PLR. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research. Front Pharmacol. 2018;9:913.

Ramsbottom N, Hunt JN. Studies of the effect of metoclopramide and apomorphine on gastric emptying and secretion in man. Gut. 1970 Dec;11(12):989-93. 

Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced Serotonin Syndrome. Intern Med. 2017;56(6):737-739. 

McGovern EM, Grevel J, Bryson SM. Pharmacokinetics of high-dose metoclopramide in cancer patients. Clin Pharmacokinet. 1986 Nov-Dec;11(6):415-24. 

Bauer M, Barna S, Blaickner M, Prosenz K, Bamminger K, Pichler V, Tournier N, Hacker M, Zeitlinger M, Karanikas G, Langer O. Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [¹¹C]Metoclopramide. Mol Imaging Biol. 2021 Apr;23(2):180-185.

Chua EW, Harger SP, Kennedy MA. Metoclopramide-Induced Acute Dystonic Reactions May Be Associated With the CYP2D6 Poor Metabolizer Status and Pregnancy-Related Hormonal Changes. Front Pharmacol. 2019;10:931. 

Trapnell BC, Mavko LE, Birskovich LM, Falko JM. Metoclopramide suppositories in the treatment of diabetic gastroparesis. Arch Intern Med. 1986 Nov;146(11):2278-9. 

Gajendran M, Sarosiek I, McCallum R. Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. Expert Rev Endocrinol Metab. 2021 Mar;16(2):25-35.

Lehmann CR, Heironimus JD, Collins CB, O’Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Clin Pharmacol Ther. 1985 Mar;37(3):284-9.

Davison SN, Tupala B, Wasylynuk BA, Siu V, Sinnarajah A, Triscott J. Recommendations for the Care of Patients Receiving Conservative Kidney Management: Focus on Management of CKD and Symptoms. Clin J Am Soc Nephrol. 2019 Apr 05;14(4):626-634.

Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. Obstet Gynecol. 2018 Jan;131(1):e15-e30.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 15, 2023. Metoclopramide. [PubMed]27.

Moos DD, Hansen DJ. Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs. 2008 Oct;23(5):292-9.

Donnet A, Harle JR, Dumont JC, Alif Cherif A. Neuroleptic malignant syndrome induced by metoclopramide. Biomed Pharmacother. 1991;45(10):461-2. [PubMed]29.

Gupta S, Nihalani ND. Neuroleptic Malignant Syndrome: A Primary Care Perspective. Prim Care Companion J Clin Psychiatry. 2004;6(5):191-194. 

Ponte CD, Nappi JM. Review of a new gastrointestinal drug–metoclopramide. Am J Hosp Pharm. 1981 Jun;38(6):829-33.

Koban Y, Ekinci M, Cagatay HH, Yazar Z. Oculogyric crisis in a patient taking metoclopramide. Clin Ophthalmol. 2014;8:567-9. 

Mary AM, Bhupalam L. Metoclopramide-induced methemoglobinemia in an adult. J Ky Med Assoc. 2000 Jun;98(6):245-7.

Tanishima K, Tanimoto K, Tomoda A, Mawatari K, Matsukawa S, Yoneyama Y, Ohkuwa H, Takazakura E. Hereditary methemoglobinemia due to cytochrome b5 reductase deficiency in blood cells without associated neurologic and mental disorders. Blood. 1985 Dec;66(6):1288-91.

Nagahama S, Fujimaki M, Kawabe H, Nakamura R, Saito I, Saruta T. Effect of metoclopramide on the secretion of aldosterone and other adrenocortical steroids. Clin Endocrinol (Oxf). 1983 Mar;18(3):287-93.

Upputuri S, Prasad S. Metoclopramide-induced delayed non-thrombocytopenic purpuric rash. Clin Drug Investig. 2006;26(12):745-7.

Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Drug Saf. 2016 Jul;39(7):675-87. [PubMed]37.

Anfinson TJ. Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide. Psychopharmacol Bull. 2002 Winter;36(1):82-93. 

Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007 Oct;3(5):929-51.

Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol. 1975 Feb;2(1):57-63. 

Lai AA, Schroeder DH. Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry. 1983 May;44(5 Pt 2):82-4.

Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol. 2010 Jun;50(6):714-20. 

Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission. Case Rep Med. 2016;2016:7128909.

Igata R, Hori H, Atake K, Katsuki A, Nakamura J. Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatr Dis Treat. 2016;12:2279-81.

Pietrzko P, Zakrzewski A, Matuszewski T, Kruszewski J. Angioneurotic edema: a rare case of hypersensitivity to metoclopramide. Postepy Dermatol Alergol. 2013 Apr;30(2):117-8.

Weinstein RB, Fife D, Sloan S, Voss EA, Treem W. Prevalence of Chronic Metoclopramide Use and Associated Diagnoses in the US Pediatric Population. Paediatr Drugs. 2015 Aug;17(4):331-7.

Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J, Anouar Y, Kuhn JM, Yon L, Lefebvre H. Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer. 2009 Mar;16(1):281-90. 

Xu D, Ham AG, Tivis RD, Caylor ML, Tao A, Flynn ST, Economen PJ, Dang HK, Johnson RW, Culbertson VL. MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia. EBioMedicine. 2017 Dec;26:132-137.

Avalos DJ, Sarosiek I, Loganathan P, McCallum RW. Diabetic gastroparesis: current challenges and future prospects. Clin Exp Gastroenterol. 2018;11:347-363.

Nimmo WS. Drugs, diseases and altered gastric emptying. Clin Pharmacokinet. 1976;1(3):189-203.

Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharmacol Ther. 1984 Dec;36(6):724-30.

Wadhwa NK, Schroeder TJ, O’Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987 Feb;19(1 Pt 2):1730-3.

Meyers RS, Thackray J, Matson KL, McPherson C, Lubsch L, Hellinga RC, Hoff DS. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191.

By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-694.

Gralla RJ. Metoclopramide. A review of antiemetic trials. Drugs. 1983 Feb;25 Suppl 1:63-73.

Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch Fam Med. 1992 Nov;1(2):271-8.

Casey DE. Tardive dyskinesia. West J Med. 1990 Nov;153(5):535-41.

Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985 Oct 05;291(6500):930-2.

Chang MY, Lin KL, Wang HS, Wu CT. Drug-Induced Extrapyramidal Symptoms at the Pediatric Emergency Department. Pediatr Emerg Care. 2020 Oct;36(10):468-472. 

Pringsheim T, Doja A, Belanger S, Patten S., Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011 Nov;16(9):590-8.

Fog AF, Kvalvaag G, Engedal K, Straand J. Drug-related problems and changes in drug utilization after medication reviews in nursing homes in Oslo, Norway. Scand J Prim Health Care. 2017 Dec;35(4):329-335.

Sridharan K, Sivaramakrishnan G. Interventions for treating nausea and vomiting in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1143-1150.

İlaç genel bilgileri

Sifar İlaçları Ticaret ve Sanayi A.Ş.

Geri Ödeme Kodu	A04977
Satış Fiyatı	45.06 TL [ 24 Nov 2023 ]
Önceki Satış Fiyatı	45.06 TL [ 17 Nov 2023 ]
Original / Jenerik	Jenerik İlaç
Reçete Durumu	Normal Reçeteli bir ilaçdır.
Barkodu	8699506012055
Etkin Madde	Metoklopramid Hcl
ATC Kodu	A03FA01
Birim Miktar	10
Birim Cinsi	MG
Ambalaj Miktarı	30